Canada markets open in 8 hours 46 minutes

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1800-0.0400 (-1.80%)
At close: 04:00PM EDT
2.2189 +0.04 (+1.78%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.2200
Open2.2700
Bid2.1300 x 100
Ask2.1900 x 400
Day's Range2.1599 - 2.3600
52 Week Range1.8800 - 17.8250
Volume427,979
Avg. Volume1,304,406
Market Cap116.931M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-3.6400
Earnings DateNov 11, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
  • GlobeNewswire

    ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today that management will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 17 – 19, 2024. Format: Fireside chat with analyst, Li Watsek and 1x1 meetingsDate: Tuesday, September 17, 2024 Tim

  • GlobeNewswire

    ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

    Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myelomaSOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the first patients have been dosed in an arm of the randomized UMBRELLA phase 1/2 clin

  • GlobeNewswire

    ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. “Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications,” said Jas